Establishment of a safe dose for oral ALA administration For 30 days post-aminolevulinic acid dose [clinicaltrials_resource:1a594bf25e14deecf6219b5dd2562e36]
Using National Cancer Institute (NCI) Common Toxicity Criteria to quantify toxicity following ALA administration. We will use descriptive statistics to analyze the safety data, based on NCI toxicity criteria.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Establishment of a safe dose for oral ALA administration For 30 days post-aminolevulinic acid dose [clinicaltrials_resource:1a594bf25e14deecf6219b5dd2562e36]
Using National Cancer Institute (NCI) Common Toxicity Criteria to quantify toxicity following ALA administration. We will use descriptive statistics to analyze the safety data, based on NCI toxicity criteria.
Bio2RDF identifier
1a594bf25e14deecf6219b5dd2562e36
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1a594bf25e14deecf6219b5dd2562e36
measure [clinicaltrials_vocabulary:measure]
Establishment of a safe dose for oral ALA administration
time frame [clinicaltrials_vocabulary:time-frame]
For 30 days post-aminolevulinic acid dose
description
Using National Cancer Institut ...... ased on NCI toxicity criteria.
identifier
clinicaltrials_resource:1a594bf25e14deecf6219b5dd2562e36
title
Establishment of a safe dose f ...... post-aminolevulinic acid dose
@en
type
label
Establishment of a safe dose f ...... 94bf25e14deecf6219b5dd2562e36]
@en